Ginkgo bioworks stock prediction.

Nov 24, 2023 · Ginkgo Bioworks ( DNA 10.85%) is your classic high-risk, high-reward investment. The cell programming company isn't generating great results right now, its operations remain unprofitable, and... May 2, 2022 · We asked three Motley Fool contributors to pick beaten-down stocks they think can deliver 5x gains by 2030. Here's why they chose CRISPR Therapeutics ( CRSP -0.74%), Ginkgo Bioworks Holdings ( DNA ... About Ginkgo Bioworks. Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse ...Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 4.1 ...Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Ginkgo’s market debut is one of the largest in biotech history.

Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for DNA stock stock is $1.88, which predicts an increase of 45.74%. The lowest target is $1.25 and the highest is $2.50. On average, analysts rate DNA stock stock as a sell.BOSTON, Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across …

Forecast Spread, -103 -51,3 -100.02%, -1 606 -64,7 -2381.73%, -593 ... Annual profits - Rate of surprise. Stock · Equities · Stock Ginkgo Bioworks Holdings, Inc.

733.3157. 57.0849. -288.9. -6,916. Get the detailed quarterly/annual income statement for Ginkgo Bioworks Holdings, Inc. (DNA). Find out the revenue, expenses and profit or loss over the last ... 15.05% of Ginkgo Bioworks stock is owned by insiders. Learn more on DNA's insider holdings. Which Ginkgo Bioworks insiders have been buying company stock? The following insider purchased DNA shares in …BOSTON, Sept. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced the launch of Ayana Bio to enable a ...Find Salaries by Job Title at Ginkgo BioWorks. 25 Salaries (for 18 job titles) • Updated Oct 29, 2023. How much do Ginkgo BioWorks employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips.Ginkgo Bioworks is a company with a lot of potential but also a lot of associated risk. Check out why I rate DNA stock an avoid for now.

Ginkgo Bioworks Holdings Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Ginkgo Bioworks Holdings Inc. Quarterly; Annual; Actual Analyst Range Consensus. 0.20 0.00-0.20-0.40.

Ginkgo Bioworks (NYSE: ... Forward-looking statements are predictions, ... There’s still plenty of yield in the stock market even with the recent rally that has resulted in a 19% year-to-date ...

Next-generation biotech Ginkgo Bioworks Holdings ( DNA -3.50%) was one of the star stocks in its sector this week. According to data compiled by S&P Global Market Intelligence, the company's share ...Currently 13 wall-street analysts regularly analyze the financials of Ginkgo Bioworks Holdings Inc on a frequent basis to provide recommendations along with target share price. 13 analysts offering 12-month price forecasts for Ginkgo Bioworks Holdings Inc (DNA) have a share price target of $4.02. This median of share price forecast represents a ...We expect investors to focus on the sales performance of Ginkgo Bioworks Holdings, Inc.’s DNA two business units when the company reports third-quarter 2023 results on Nov 8 after market close.Feb 7, 2023 · 2. Ginkgo Bioworks. Ginkgo Bioworks (DNA 5.80%) is also a holding in the Ark Innovation ETF and the Ark Genomic Revolution ETF. The company is a leader in cell programming technology that's used ... Nov 24, 2023 · Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion. Evgenii Kovalev. Ginkgo Bioworks (NYSE:DNA) is still finding its feet as a public company, with the stock continuing to decline on the back of valuation concerns and declining Biosecurity revenue ...

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and ...The current Ginkgo Bioworks Holdings [ DNA] share price is $1.43. The Score for DNA is 19, which is 62% below its historic median score of 50, and infers higher risk than normal. DNA is currently trading in the 10-20% percentile …InterContinental Hotels Group Stock Forecast, "IHG" Share Price Prediction Charts . 1 comment; a month ago; swgray09_2867 — This is a Great share to own for the long term will reach £75 many wealthy investors getting on board. I own this one myself.The current price Ginkgo Bioworks Holdings (DNA) is trading at is $1.41, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular ChannelsOct 18, 2023 · Ginkgo Bioworks (NYSE: DNA) sells something very original: the large-scale design and production of organisms. And thanks to its innovations, the company has increased revenue almost 800% over the ... Sep 17, 2021 · Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Ginkgo’s market debut is one of the largest in biotech history. Forward-Looking Statements of Ginkgo Bioworks This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, current expectations, operations and anticipated results of operations, both ...

Track Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A (DNA) Stock Price, Quote, latest community messages, chart, news and other stock related ...Ginkgo Bioworks Holdings Stock Forecast, - WalletInvestor.com

Ginkgo Bioworks looks cheaper now than it has at pretty much any other time as a public company. That being said, a P/S over 5 with declining revenue and increasing operating losses isn't exactly ...Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business ...Nov 14, 2023 · Future criteria checks 2/6. Ginkgo Bioworks Holdings is forecast to grow earnings and revenue by 57.8% and 24.3% per annum respectively. EPS is expected to grow by 65.1% per annum. Return on equity is forecast to be -62.6% in 3 years. Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will ...More stock info. Press Releases Details. ... Forward-looking statements are predictions, ... GINKGO BIOWORKS MEDIA CONTACT: [email protected] . ELANCO INVESTOR CONTACT Katy Grissom +1.317.273.9248 [email protected]. ELANCO MEDIA CONTACT Colleen Parr DekkerThe analysts covering Ginkgo Bioworks Holdings, Inc. delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon.Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock ...Ginkgo's business model has many nuances that are not well understood, and its Q1 results were something of a mixed bag. Click here to read more on DNA stock.Their UNCY share price targets range from $4.00 to $24.00. On average, they expect the company's share price to reach $10.83 in the next twelve months. This suggests a possible upside of 2,013.8% from the stock's current price. View analysts price targets for UNCY or view top-rated stocks among Wall Street analysts.Forward momentum convinced Wood to buy more than 3 million shares of Archer Aviation stock last week. Now, Ark Invest's stake in the up-and-coming air taxi provider is more than 3 times the size ...

The average analyst rating for DNA stock from 4 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market …

Ginkgo Bioworks Holdings, Inc ... Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its ... Forward-looking statements are predictions, ...

See Ginkgo Bioworks Holdings, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy.Find the latest Ginkgo Bioworks Holdings, Inc. DNA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range investment ratingAbout Ginkgo Bioworks Holdings Inc. Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food ...Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance ...Ginkgo Bioworks (NYSE: ... Forward-looking statements are predictions, ... There’s still plenty of yield in the stock market even with the recent rally that has resulted in a 19% year-to-date ...Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and ...Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. [Read more] In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021.Ginkgo Bioworks Holdings (DNA – Research Report) received a Sell rating and a $1.25 price target from Goldman Sachs analyst Matthew Sykes today. The company’s shares closed yesterday at $1.68.Ginkgo Bioworks (DNA 8.53%) is a biotech unlike any other, and it's no surprise why it's consistently attracting the attention of bigwig portfolio managers like Cathie Wood. Wood's confidence in ...

Oct 6, 2021 · In about an hour following the publication of Scorpion’s 175-page report, Ginkgo’s stock price dropped at least 20%, down to about $9.50 a share. Barron's Stock Pick; Synthetic Biology Could Be the Next Big Thing. Here’s How to Play It. By Andrew Bary. Updated July 16, 2021, 10:38 pm EDT / Original July 16, 2021, 7:42 pm EDT.Evgenii Kovalev. Ginkgo Bioworks (NYSE:DNA) is still finding its feet as a public company, with the stock continuing to decline on the back of valuation concerns and declining Biosecurity revenue ...Instagram:https://instagram. dow jones industrial stocks listnew energy stocksaffirm interest ratei bonds rate may 2023 May 12, 2023 · Ginkgo Bioworks Holdings' estimated fair value is US$1.81 based on 2 Stage Free Cash Flow to Equity Current share price of US$1.33 suggests Ginkgo Bioworks Holdings is potentially 26% undervalued Oct 14, 2021 · Today, high-profile growth company Ginkgo Bioworks (NYSE: DNA) is one that’s generating a lot of attention in the market. Indeed, given today’s 14% rise in DNA stock, investors who put this ... top rated health insurance californiahow to make profit in forex trading The last reported sale price of Ginkgo's Class A common stock on November 15, 2022 was $2.67 per share. The underwriter proposes to offer for sale the shares of common stock from time to time in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related ...May 10, 2023 · On May 10, Ginkgo Bioworks will report earnings from Q1. Analysts predict losses per share of $0.085. Go here to track Ginkgo Bioworks stock price in real-time ahead of earnings. servicenow stocks Ginkgo Bioworks, the synthetic ... The $364 million number represents the price of Ginkgo's stock on November 17, 2021, when shares were trading at $13.59 apiece and the value exceeded $20 billionCambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform ...